PMV Pharmaceuticals Reports Q2 2026 Financial Results

What Happened
PMV Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2026 in a press release issued and filed on August 14, 2026. The press release is attached to the Current Report on Form 8‑K as Exhibit 99.1 and is incorporated by reference. The filing was signed by Michael Carulli, Chief Financial Officer (Principal Financial and Accounting Officer).

Key Details

• Filing date: August 14, 2026 (Form 8‑K Items 2.02 and 9.01).
• Reporting period: quarter ended June 30, 2026 (second quarter, 2026).
• Disclosure: results of operations and financial condition announced via press release (Exhibit 99.1).
• Authorized signature: Michael Carulli, Chief Financial Officer.

Why It Matters
This 8‑K notifies investors that PMV published its quarterly earnings and other financial results — key information for assessing recent company performance (earnings, revenue, cash position and guidance typically appear in the attached press release). Retail investors should read the Exhibit 99.1 press release linked in the filing for the actual financial figures and management commentary to evaluate impacts on valuation, cash runway, and near‑term strategy.